WO2001068070A8 - Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis - Google Patents
Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesisInfo
- Publication number
- WO2001068070A8 WO2001068070A8 PCT/IT2001/000113 IT0100113W WO0168070A8 WO 2001068070 A8 WO2001068070 A8 WO 2001068070A8 IT 0100113 W IT0100113 W IT 0100113W WO 0168070 A8 WO0168070 A8 WO 0168070A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- spirolaxin
- treatment
- diseases associated
- abnormal angiogenesis
- angiogenesis
- Prior art date
Links
- CZIMFHQXGMXDMO-DGROVODQSA-N (3r)-5-hydroxy-7-methoxy-3-[5-[(2r,5r,7r)-2-methyl-1,6-dioxaspiro[4.5]decan-7-yl]pentyl]-3h-2-benzofuran-1-one Chemical compound C([C@H](O1)CCCCC[C@@H]2C=3C=C(O)C=C(C=3C(=O)O2)OC)CC[C@@]21CC[C@@H](C)O2 CZIMFHQXGMXDMO-DGROVODQSA-N 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44533/01A AU4453301A (en) | 2000-03-13 | 2001-03-07 | Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2000A000129 | 2000-03-13 | ||
IT2000RM000129A IT1317001B1 (en) | 2000-03-13 | 2000-03-13 | USE OF SPIROLAXIN FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH AN ALTERED ANGIOGENESIS. |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001068070A2 WO2001068070A2 (en) | 2001-09-20 |
WO2001068070A8 true WO2001068070A8 (en) | 2001-11-08 |
WO2001068070A3 WO2001068070A3 (en) | 2002-04-18 |
Family
ID=11454527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2001/000113 WO2001068070A2 (en) | 2000-03-13 | 2001-03-07 | Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4453301A (en) |
IT (1) | IT1317001B1 (en) |
WO (1) | WO2001068070A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20010136A1 (en) * | 2001-03-16 | 2002-09-16 | Sigma Tau Ind Farmaceuti | USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF THE PPAR-GAMMA RECEPTOR. |
ITMI20041279A1 (en) * | 2004-06-24 | 2004-09-24 | Pharmaproducts Uk Ltd | USE OF TRIFLUOROACETATE CALCIUM FOR THE PREPARATION OF ANTI-ANGIOGENETIC EFFECT MEDICATIONS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174710B1 (en) * | 1994-08-09 | 2001-01-16 | Pfizer Inc. | Spirolaxine derivatives for treating gastrobuodenal diseases |
JPH107557A (en) * | 1996-06-17 | 1998-01-13 | Banyu Pharmaceut Co Ltd | Antitumor substance spirolaxine |
US6538103B1 (en) * | 1998-07-14 | 2003-03-25 | Bristol--Myers Squibb Company | Lysine binding fragments of angiostatin |
-
2000
- 2000-03-13 IT IT2000RM000129A patent/IT1317001B1/en active
-
2001
- 2001-03-07 WO PCT/IT2001/000113 patent/WO2001068070A2/en active Application Filing
- 2001-03-07 AU AU44533/01A patent/AU4453301A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001068070A3 (en) | 2002-04-18 |
ITRM20000129A0 (en) | 2000-03-13 |
IT1317001B1 (en) | 2003-05-26 |
ITRM20000129A1 (en) | 2001-09-13 |
AU4453301A (en) | 2001-09-24 |
WO2001068070A2 (en) | 2001-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU1025795A (en) | Prolineamide derivatives | |
AU1529901A (en) | Compounds | |
GB0105772D0 (en) | Use | |
MY134892A (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use | |
WO2002039954A3 (en) | Novel compounds | |
AU7622000A (en) | Compounds for the treatment of viral-mediated diseases | |
WO2002092072A3 (en) | Drugs for the treatment of the alzheimer disease | |
WO2002011737A3 (en) | Anti-inflammatory medicament | |
SE0101082D0 (en) | Novel use | |
AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
WO2002026732A1 (en) | Benzodiazepine derivative | |
MXPA05006889A (en) | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. | |
WO2001016096A3 (en) | Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia | |
WO2001068070A8 (en) | Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis | |
WO2003063858A3 (en) | Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases | |
WO1998056759A3 (en) | Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same | |
AU1651201A (en) | Amidinophenylpyruvic acid derivative | |
WO2003091243A8 (en) | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics | |
WO2000076966A3 (en) | Indolinylamide derivatives and the use thereof as antiviral drugs | |
WO2001068071A3 (en) | Use of natural chrysanthone compounds having antiangiogenic activity | |
NO20021710L (en) | Use of 2-amino-3,4-dihydroquinazolines for the preparation of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions | |
NO20014889D0 (en) | Process for the preparation of medical agents | |
WO2004035031A3 (en) | Treatment of uveal melanoma | |
EP1464636A4 (en) | Novel substance having antitumor/anti-inflammatory activity | |
AU1434201A (en) | Antithrombotic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |